Cellares, GenomeFrontier to assess automated GF-CART01 production

Cellares and GenomeFrontier Therapeutics are to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform. The partnership aims to assist GenomeFrontier’s clinical activities for GF-CART01 in the US. GF-CART01 has shown positive clinical trial data in Taiwan. Credit: ultramansk / Shutterstock.com. Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform. The collaboration, which marks Cellares’ first development project in Asia, will explore adapting GenomeFrontier’s virus-free process to the Cell Shuttle system. LOA and PTSR Model Gene-Modified…

Salong Debbarma · 2026-09-17

Cellares and GenomeFrontier Therapeutics are to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.

Source: Pharmaceutical Technology